SGLT2 Inhibitors Match Metformin Across Most Polycystic Ovary Syndrome Clinical Outcomes
A systematic review of five randomized trials found SGLT2 inhibitors showed no overall superiority over metformin in women with polycystic ...
A systematic review of five randomized trials found SGLT2 inhibitors showed no overall superiority over metformin in women with polycystic ...
In a preclinical model of chronic pressure overload, eight weeks of empagliflozin treatment significantly reduced mortality, attenuated ventricular remodeling, and ...
In the randomized PROVE trial, empagliflozin significantly reduced functional tricuspid regurgitation severity in heart failure patients with preserved ejection fraction ...
The PROVE trial demonstrates that empagliflozin can reduce tricuspid regurgitation severity, suggesting the therapeutic effect may occur at the valve ...
A meta-analysis of ten studies suggests GLP-1 receptor agonists and SGLT-2 inhibitors reduce major adverse cardiovascular events in patients with ...
An updated systematic review and meta-analysis reveals finerenone-based treatment reduces composite kidney and cardiovascular events in diabetic kidney disease.
Researchers developed two separation-free mathematical spectrophotometry methods using ethanol to simultaneously measure empagliflozin and sitagliptin in commercial tablets.
A health-economic microsimulation found that adding empagliflozin or semaglutide to standard diabetes care cost-effectively slows diabetic nephropathy in Germany.
A randomized controlled trial revealed that a single pre-procedural dose of empagliflozin attenuated oxidative DNA damage and modulated inflammatory glycosylation ...
A new phase 2a trial protocol aims to evaluate the pharmacokinetics and safety of empagliflozin in children with Duchenne muscular ...
In a randomized controlled trial published in Discover Endocrinology and Metabolism, researchers compared the effects of imeglimin and empagliflozin on ...
A comprehensive literature review evaluates empagliflozin's efficacy, safety, and cardiorenal benefits in patients with and without diabetes.
In ambulatory heart failure, lower serum chloride levels are associated with poor outcomes independently of sodium, while the clinical benefits ...
A German health insurance model projects that early empagliflozin after heart attack yields modest quality-adjusted survival gains at an incremental ...
A new review finds that combining SGLT2 inhibitors with GLP-1 receptor agonists in heart failure is mechanistically plausible and generally ...
A preclinical study reports that berberine reduced kidney injury in diabetic mice and curbed glucose uptake in kidney cells through ...
Three-hour pretreatment with empagliflozin reduced multiple electrophysiological signs of arrhythmia in isolated mouse and rabbit heart cells from two non-ischemic ...
A new study links SGLT2 inhibitor therapy with reduced circulating activin A, improved right-heart function, and modulation of BMP/activin signaling ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.